Maeda H, Kurokawa T: Regulatory review time for Approval of oncology drugs in Japan between 2001 and 2014.Considerations of changes, factors that affect review time, and difference with the United States. J Clin Pharmacol, 55: 481-489, 2015
Format and Content of a REMS Document Guidance for Industry, https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM184128.pdf